Over the last year, many reliable genetic associations with complex diseases have been reported including some associations with complex neurological and psychiatric diseases. Many of these disease associations do not map to coding changes in protein open reading frames, but rather are believed to lead to genetic variability in gene expression and splicing. Such effects can be dissected by studies, which use genetic variability in mRNA expression as quantitative traits and regress these traits against genotype.
Neurodegenerative and neuropsychiatric diseases pose an enormous societal challenge. Alzheimer's and Parkinson's disease, the two most common, have a prevalence of $20 and 5% in those over 80 years of age, while schizophrenia and bipolar syndromes each afflict $1% of the population. Current treatment strategies for all these diseases are palliative and there is a clear need to develop disease-modifying therapies based on an understanding of aetiology and pathogenesis.
Although the genes underlying the Mendelian forms of neurodegenerative diseases have been identified, the aetiology of the vast majority of cases of all these diseases has remained obscure. Identifying the genetic risk factors which underlie these disorders has proved to be a surprisingly difficult task. However, in the last two years genome wide association (GWA) studies have provided significant new insights. Using SNP chips to screen simultaneously for $500 000 genetic polymorphisms in typically >1000 cases and >1000 controls, hundreds of risk factors have been identified. While some of these risk loci have been assigned to coding changes in genes, the majority have not, and many have not even mapped to recognizable genes.
Thus, even though GWA studies are providing valuable information, used alone this information does not allow us to dissect the pathogenesis of these disorders. Bridging this gap in our understanding, requires an appreciation of the fact that while complex disorders have been simplified and coded as binary states (diseased or not diseased) for the purposes of the GWA studies, in most cases clinical diagnosis depends on meeting a threshold for disease. For example, it is well recognized that clinical symptoms are not apparent in Parkinson's disease until $80% of dopaminergic neurons are lost within the substantia nigra [1, 2] . This leads to the idea that there are likely to be intermediate continuous phenotypes (distinct from disease states), which can be measured in individuals and which can be correlated to the risk of developing a neurological or psychiatric John Hardy is a human geneticist who has worked extensively on the genetics of neurological and psychiatric disorders. He trained as a neuropharmacologist at Imperial College London, but took up human molecular genetics while he was an Assistant Professor at St Mary's Hospital Medical School. He worked in the USA for 15 years, returning to University College London in 2007 to hold a Chair in Neuroscience. disease ( Figure 1 ). Furthermore, these continuous phenotypes are likely to overlap with normality. Conceptually this can be compared to the measurement of continuous phenotypes such as hypertension and hypercholesterolaemia, which are present in the normal population and contribute to the process of atherosclerosis, but are not inevitably followed by myocardial infarction. On this basis it seems likely that by relating genotypic information to relevant intermediate continuous phenotypes in normal populations we can improve our understanding of complex neurological and psychiatric diseases.
The most obvious and generally applicable continuous phenotype to consider is mRNA expression. In fact, since the completion of the Human Genome Project and the discovery that the human genome contains $25 000 genes as opposed to the original estimate of 100 000, there has been mounting evidence of the importance of transcriptional regulation in cellular function. This has led to an appreciation that human disease may be caused not only by changes in gene coding and consequently protein sequences, but also by changes in mRNA regulation (whether quantitative or qualitative) [2, 3] . In fact, it may be that inherited differences in transcriptional regulation are the most important drivers of pathology in common diseases, including complex neurological and psychiatric conditions. If common heritable differences in transcriptional regulation can drive pathology in the human central nervous system, then we would expect to find strong associations between the risk SNPs identified in GWA studies for neurological diseases and specific mRNA expression phenotypes of functional significance in control human brain.
The study of mRNA expression in brain tissue has specific challenges. Most important, is the issue of tissue access. Although it is conceivable that some surgical brain specimens could be considered control samples, in practice research is restricted to the use of post-mortem samples. These samples are far from ideal, being subject to changes in gene expression as a function of the mode of death and RNA degradation secondary to post-mortem delays and tissue handling. Nonetheless, there is evidence to suggest that sufficiently high quality mRNA can be extracted from post-mortem brain samples for use in genotypic gene expression studies [4, 5] . Paired SNP and expression arrays have been applied to postmortem human cortical tissue and have successfully demonstrated both cis and trans effects of SNPs on mRNA transcript levels and splicing [4] [5] [6] . The structurally and functionally diverse nature of the human brain also presents challenges with regard to tissue sampling. Even within brain regions considered to be structurally very similar, such as the cerebral cortex, differences in the cytoarchitecture exist and there are multiple cell types. These differences are functionally significant as demonstrated by the close correlation between cortical function and specific Brodmann areas (as defined solely on the basis of neuronal organization). Therefore, any attempt to define the inheritance of gene expression within the adult human brain would require precise sampling of multiple brain areas.
Setting aside these practical difficulties and given that the premise of this approach is the belief that risk SNPs mediate their effects by regulating mRNA expression, it is important to define in more detail what that might mean. The most obvious target for transcriptome regulation is mRNA quantity. There is already strong evidence to suggest that mRNA expression is a quantitative trait which can be inherited [7, 8] . The term expression quantitative trait loci (eQTL) has been used to describe genetic loci strongly associated with the expression levels of particular genes and SNPs have already been shown to act as eQTLs in human brain tissue [4] [5] [6] . More recently it has also been possible to demonstrate the effects of genetic loci on mRNA structure. Processing and in particular splicing of precursor mRNA can be influenced by specific SNPs within human brain tissue [4] and these SNPs have been termed splicing quantitative trait loci (sQTLs). Although at present these properties have been considered separately, it is very likely that effects on overall mRNA expression levels and splicing of a particular gene are strongly related. Different splice variants may have different stabilities resulting in changes in overall transcript levels. Alternatively high expression of precursor mRNA could saturate the capacity of the splicing machinery resulting in a change in the splice variants produced. These effects could result in a given genetic locus acting predominantly as an eQTL in one tissue state and as a sQTL in another. The ability to make simultaneous mRNA measurements from a single biological sample has also revealed another potentially heritable feature of mRNA regulation namely co-expression and expression networks. Since cellular processes depend on multiple genes acting in concert this may be a more natural way to describe mRNA expression phenotypes. The identification of functional gene expression modules within human brain using network analysis supports this approach [6] .
Clearly the discovery of eQTLs and sQTLs depends on being able to accurately measure RNA quantity and quality. At present the most commonly used method is DNA microarrays. Technological advances have made it possible to make simultaneous quantitative and qualitative measurements about all known human genes using small starting amounts of human tissue. However, there are some limitations intrinsic to hybridization-based array technology. Most importantly, a priori knowledge of the interesting RNA sequences is required in order to design the relevant probes. Quantitative values are inferred from hybridization-dependent signals making it difficult to compare experiments and rare transcripts are unlikely to be detected even when the relevant probes are present due to significant background. Furthermore, while exon-specific probes have made it possible to detect splice variation (even if we assume exons have been correctly predicted) in the vast majority of cases it is not possible to determine the actual transcripts within the sample. This is because similar exon-specific probe signals for a given gene can be produced by a variety of possible splice variants. There are also some challenges relating to the use of DNA microarrays specifically within the context of genotypic gene expression studies. Alterations in hybridization efficiency due to the presence of coding SNPs within probes can potentially result in differences in mRNA expression being attributed to the SNP. Although the problem of SNPs within probes is well recognised, it remains unclear if it is causing systematic errors in genotypic gene expression studies. In one of the largest studies to date, Emilsson et al. [9] found that there was no evidence of systematic or specific hybridization artefacts from the presence of SNPs within probes in their eQTL data. Many of these concerns could potentially be solved by using RNA-sequencing technology. Developments in high-throughput sequencing are already providing insights into transcriptional regulation within human tissues [10] . In particular, using sequencing rather than hybridization requires less a priori knowledge and has the capacity to distinguish and quantify closely related mRNA isoforms. However, the financial and analytical burden of this technology is still too high for it to be used as a replacement for microarray technology at present. This situation is likely to change and we predict that RNA sequencing will ultimately overtake hybridization technologies as the method of choice for gene expression surveying.
Despite these caveats, genotypic gene expression studies have successfully identified QTLs in a range of tissues using microarray technology for the generation of both genomic and transcriptomic data. These studies have demonstrated that the proportion of the inter-individual variation in mRNA expression which can be explained by a given SNPand all loci in linkage disequilibrium (LD)-can be substantial. Although most studies agree on an average eQTL heritability of $25% [9, 11, 12] , a recent study by Schadt and colleagues [13] investigating gene expression in human liver reported that the magnitude of the effects ranged from SNPs that explained 2% to those that explained 90% of the in vivo expression variation. Although the lower limit of eQTL heritability is most likely to represent the detection limit imposed by study design and sample number, the finding that up to 90% of in vivo variation in gene expression can in some cases be explained by a given SNP warrants discussion. At first glance these findings may suggest that gene expression is sometimes 'hard-wired'. However, it is more likely that the heritability of gene expression is variable and depends on the cell/tissue state. Whereas it is conceivable that gene expression may be largely genetically determined during some developmental stages or stress states (e.g. hypoxia) at other times the expression of the same gene may be more heavily influenced by environmental factors. It is also important to recognise that while eQTL measurements are made by associating a single SNP with a single gene expression level, eQTL heritability is actually a measure of the effect of that SNP and all genetic loci in LD. Thus, it may be more natural and statistically powerful to design studies which explicitly investigate allele-specific as opposed to genotype-specific gene expression. This is a particularly important consideration in the detection of trans-acting eQTLs/sQTLs. To date, the vast majority of the eQTLs/sQTLs identified are cis-acting. Although this may be because trans effects are smaller, it is more likely to be due to the reduction in power to detect these effects in all studies. While cis regions are candidate regions to contain regulatory elements that influence the proximal genes, it is harder to select a priori equivalent 'trans regions' from the rest of the genome resulting in a massive increase in the number of hypothesis tests required. Nonetheless Myers and colleagues [6] were able to identify trans-acting SNPs in human cortex (lowest P-value ¼ 7.66 e À11 ). Thus, the identification of eQTLs and sQTLs is well within the realm of possibility with present technology.
However, given that the inspiration for genotypic gene expression studies is the understanding of the molecular mechanisms underlying risk SNPs, we are primarily interested in the detection of eQTL/sQTLs, which are also recognized disease risk SNPs. While it may be tempting to believe that the effects of risk SNPs on transcription will be easier to detect because SNPs which confer a high level of disease risk do so by producing large magnitude effects on gene expression, this need not be true and there is little evidence to support this claim. However, assuming that risk and non-risk SNPs have similar amplitude effects on gene expression, there is empirical evidence to support the feasibility of genotypic gene expression studies in human brain [4, 14] . More importantly, there are examples in the literature to suggest that genotypic gene expression studies can indeed improve our understanding of risk SNPs. Integrative genomics has been used to help identify candidate genes and provide independent support for specific molecular processes. By coupling genetic findings with genome-wide gene expression data from EpsteinBarr virus-transformed lymphoblastoid cells it has been possible to demonstrate that the risk SNPs with the strongest association to asthma were consistently associated with the levels of ORMDL2 and GSDML transcripts [15] . Using a similar approach, Myers and colleagues demonstrated that a variant of MAPT (encoding tau), known from GWAs studies to be associated with progressive supranuclear palsy, is also associated with increased expression of 4 repeat MAPT mRNA [5, 6, 16] . Therefore, this study supports the specific pathogenic role of the 4 repeat tau isoform in sporadic tauopathies, including progressive supranuclear palsy. Although these examples demonstrate the potential power of combining genome-wide gene expression studies with GWAs, an integrative approach may prove to have wider applications. Searching between the genomic and transcriptomic data sets will generate: (i) groups of expression phenotypes all influenced by a single genetic locus and (ii) groups of genetic loci all capable of producing a single expression phenotype (Figure 2 ). Combining this information with the results of GWA studies of neurological diseases, may demonstrate that apparently independent risk loci converge on a limited number of expression phenotypes, which may or may not already have been known to be clinically relevant. In the first instance this information could form the basis for the development of new biomarkers in neurology. Similarly information about signalling pathways or gene functions could be used to make sense of groups of expression phenotypes. The availability of well organised and curated gene network information, such as that available from the Gene Ontology (http://www.geneontology.org/) or Reactome projects (http://www.reactome.org/), has made this a much easier task. In this way, the identification of new therapeutic targets could be accelerated, bringing much needed treatments that much closer to reality.
In summary, there is no doubt that the identification of risk SNPs by genome wide association studies represents an enormous advance, but this can only be seen as the beginning. Further research is required to translate genetic risk loci into molecular mechanisms and ultimately therapies. We believe that genotypic gene expression studies could help to bridge this knowledge gap and rapidly provide insights into complex neurologic and psychiatric diseases.
